Notice of Ruling on Patent Infringement Lawsuit Concerning “Teribone™ Injection”
September 27, 2024
Asahi Kasei Pharma Corp.
On April 21, 2022, Asahi Kasei Pharma Corp. (Head Office: Chiyoda-ku, Tokyo; President: Yoshikazu Aoki; hereinafter “Asahi Kasei Pharma”) filed a lawsuit against Sawai Pharmaceutical Co., Ltd. (hereinafter “Sawai”) based on the process patent (Patent No. 6025881; FREEZE-DRIED PREPARATION CONTAINING HIGH-PURITY PTH AND METHOD FOR PRODUCING SAME) relating to “Teribone™ Injection” and sought an injunction against the manufacture and sale of “Teriparatide for Subcutaneous Injection 56.5 μg [SAWAI]” (a generic of “Teribone™ Injection” for osteoporosis; hereinafter “Sawai Product”) as well as compensation for damages caused by the infringement.
Asahi Kasei Pharma hereby announces that the Osaka District Court rendered a judgment in its favor on September 26, 2024. In the judgment, the Court ordered the injunction against the manufacture, sale, and offer for sale of Sawai Product manufactured using the patented process, the destruction of Sawai Product, the payment of JPY 3,064,916,243 as compensation for damages, and additional payment of late charges at the rate of 3% per annum from the time of addition of claims for damages during the process of litigation until paid.
Asahi Kasei Pharma values intellectual property rights as important management resources, and will continue to protect its intellectual property through resolute action against infringement of its intellectual property rights.